Popular on TelAve
- People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative - 206
- Mensa identifies best board games of 2025 - 174
- Is Billboard Advertising Still Effective in 2025? - 107
- Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet
- Climate Masters Inc. Poised for Record-Breaking Year in 2025
- Bluebonnet Fiber Submits Application to Expand Service to Big Wells
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- Tampa-Based Social Media Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Keenan's Caring Konnections, LLC
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
Similar on TelAve
- Premium Domain Name "Feedri.com" Now Available for Acquisition After $8,500 Offer
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
- Neoware Unveils Strategic Transformation as a Specialist "Data to Intelligence" Partner
- Phoenix Implant Clinic Introduces Upfront Cost Page to Strengthen Patient Trust
- Pregis Expands its Curbside-Recyclable Paper Packaging Portfolio with White EasyPack GeoTerra
- Advanced Dental Techniques Recognized as a Top Family Dentist for 2024
- Sumis Partners Launches, Uniting Industry Leaders to Redefine Life Sciences Consulting
Perspectives: Jellyfish Publication of an exciting new human clinical trial of proprietary KollaJell™ collagen peptide formulation
TelAve News/10863742
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports.
TEMECULA, Calif. - TelAve -- Jellyfish Publication-Certified Nutraceuticals, Inc.
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on TelAve News
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on TelAve News
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Gerald M. Haase, M.D.
Clinical Professor of Surgery, University of Colorado School of Medicine, Aurora, CO.
Neil E. Wolkodoff, PhD
Medical Program Director, Colorado Center for Health and Sports Science, Denver, CO.
May 16, 2025
Certified Nutraceuticals, Inc., a research and product development enterprise in Pauma Valley, California, U.S.A., announces the publication of an exciting new human clinical trial of its proprietary KollaJell™ collagen peptide formulation.
The research study of this unique jellyfish collagen-based supplement was published in the peer-reviewed medical source, the Journal of Clinical Research and Reports. The strength of this prospective, randomized trial is the distinctive utilization of a panel of brain function metrics from two robust, validated instruments, including a computerized neurocognitive test battery and an electroencephalographic (EEG) profile of voltage activation and wave phase pattern. Instead of evaluating only one or two parameters, this investigation assessed seven domains of cognitive function in 23 subjects who consumed KollaJell™ for a period of eight weeks.
More on TelAve News
- Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
- The Jesse Roldan Team and Biz Hub Financial Successfully Facilitate One-Day Closing for Investor Deal in Hellertown, PA
- How Does Google Crawl Websites?
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
The outcomes were clinically relevant, and all were statistically analyzed and achieved statistical significance. Standard scores matched for age and gender improved in all metrics regardless of the functional status of where the subject started. The parameters included compositive memory, neurocognitive index, visual memory, executive function and verbal memory. Under EEG monitoring conditions, the mean total reaction time and the trail-making composite test times also decreased dramatically. Topographic brain images showed voltage activation in the brain regions associated with sensory input and processing function. There were no adverse effects of consuming the supplement in any subject at any time during the study.
The importance of this pilot trial is the demonstration of a particularly extensive spectrum of beneficial results from the proprietary formulation compared to competing products that, even if helpful, provide only limited effects. In addition, the use of a marine-based natural collagen was superior to the usual animal-based products and the patented extraction process provided a greater platform of collagen types and a uniquely effective amino acid composition. This human clinical trial reinforces the concept that Certified Nutraceuticals KollaJell™ is a safe and beneficial collagen supplement that supports cognitive domains and memory and is applicable to a wide audience of potential consumers, regardless of their initial brain function status.
More on TelAve News
- $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
- Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements
- Q1 2025 Revenue Soars 92% to $1.13M on Strategic Acquisitions, Organic Growth & Breakthroughs in AI Drones & Quantum Tech: ZenaTech Stock Symbol: ZENA
- Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
- Robert Tsigler Selected by NADC as Top 1% Attorney in the U.S. for 2025
The actual medical study is available as a free open-access publication at https://www.auctoresonline.org/article/effects-of-a-jellyfish-collagen-based-amino-acid-supplement-on-cognitive-function-and-memory-a-pilot-investigation
For further information about the product or study, please contact:
Sara Alkayali at (951) 600-3899 or email: salkayali@certifiednutra.com
Source: Certified Nutraceuticals, Inc.
0 Comments
Latest on TelAve News
- L2 Aviation Honored with James A. Wuenker Growth Award by REDI Cincinnati
- APA Faces Outrage: Child Deaths and a $329 Billion Mental Health Failure
- Class of 2025 - NYC Basketball Hall of Fame
- The Smart Way to Run Your Flooring Business: Comp-U-Floor Delivers Game-Changing Flooring Industry Software
- Bluumly Chosen as Finalist for the 2025 MIT Sloan CIO Symposium's Innovation Showcase
- Live Good Relaunches "Be The Generation" Initiative to Empower Student Leadership Amid Cuts to Public Health and Education
- Host Your Next Retreat in Costa Rica: Tamarindo Bay Boutique Hotel & Studios Offers the Ideal Setting in Playa Tamarindo, Costa Rica
- Koplon Implant & Family Dentistry Receives National Recognition as One of the Best Dental Implant Practices in the U.S
- San Antonio Buyer Secures 2.375% Mortgage in 2025-Broker Reveals the Mistake Costing Buyers Thousands
- Heritage at South Brunswick Grand Opening Success!
- GTS Acquires AMT Telecom Group, Strengthening Leadership in Technology Solutions Distribution
- $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
- LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
- Marc Soucy's Newest Music Series Approaches Its One Year Mark
- Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities
- Award-winning NJ Author Celebrates New Release and Multi-Author Collaboration
- Therapy 911 Launches Mental Health Social Network to Celebrate Mental Health Awareness Month
- Bosco's Beach Launches Vacation Rentals in Panama City Beach, Florida
- $7.8M Financing Boosts NRx's Expansion with Kadima Institute Acquisition for PTSD and Depression Care: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- One Park Financial Once Again Honored with Sun Sentinel's Top Workplaces Award for the 8th Time — Achieves Best Ranking Yet in 2025